{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T18:33:04Z","timestamp":1770748384894,"version":"3.50.0"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lungcancerjournal.info","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1016\/j.lungcan.2022.10.007","type":"journal-article","created":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T21:33:55Z","timestamp":1667338435000},"page":"91-96","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Patterns of renal toxicity from the combination of pemetrexed and pembrolizumab for advanced nonsquamous non-small-cell lung cancer (NSCLC): A single-center experience"],"prefix":"10.1016","volume":"174","author":[{"given":"Andrea","family":"De Giglio","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valeria","family":"Grandinetti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marta","family":"Aprile","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Greta","family":"Borelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anita","family":"Campus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna Laura","family":"Croci Chiocchini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco","family":"Busutti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gisella","family":"Vischini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandro","family":"Di Federico","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesca","family":"Sperandi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara","family":"Melotti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Ardizzoni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gaetano","family":"La Manna","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Gelsomino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.lungcan.2022.10.007_b0005","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1093\/annonc\/mdv209","article-title":"Combining immunotherapy and anticancer agents: The right path to achieve cancer cure?","volume":"26","author":"Apetoh","year":"2015","journal-title":"Ann. Oncol."},{"issue":"14","key":"10.1016\/j.lungcan.2022.10.007_b0010","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1200\/JCO.19.03136","article-title":"Updated analysis From KEYNOTE-189: Pembrolizumab or placebo plus pemetrexed and platinum for previously untreated metastatic nonsquamous non-small-cell lung cancer","volume":"38","author":"Gadgeel","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2022.10.007_b0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2021.103302","article-title":"PD-1\/PD-L1 inhibitor monotherapy or in combination with chemotherapy as upfront treatment for advanced NSCLC with PD-L1 expression \u2265 50%: Selecting the best strategy","volume":"160","author":"Di Federico","year":"2021","journal-title":"Crit. Rev. Oncol. Hematol."},{"issue":"10","key":"10.1016\/j.lungcan.2022.10.007_b0020","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.2215\/CJN.02780312","article-title":"Onco-nephrology: Renal toxicities of chemotherapeutic agents","volume":"7","author":"Perazella","year":"2012","journal-title":"Clin. J. Am. Soc. Nephrol."},{"issue":"9","key":"10.1016\/j.lungcan.2022.10.007_b0025","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1016\/j.jtho.2020.04.021","article-title":"Renal toxicity from pemetrexed and pembrolizumab in the era of combination therapy in patients with metastatic nonsquamous cell NSCLC","volume":"15","author":"Dumoulin","year":"2020","journal-title":"J. Thorac. Oncol."},{"issue":"5","key":"10.1016\/j.lungcan.2022.10.007_b0030","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.cllc.2017.04.003","article-title":"Safety analyses of pemetrexed-cisplatin and pemetrexed maintenance therapies in patients with advanced non-squamous NSCLC: Retrospective analyses from 2 Phase III studies","volume":"18","author":"Langer","year":"2017","journal-title":"Clin. Lung Cancer."},{"issue":"4","key":"10.1016\/j.lungcan.2022.10.007_b0035","doi-asserted-by":"crossref","first-page":"1800884","DOI":"10.1183\/13993003.00884-2018","article-title":"Renal impairment during pemetrexed maintenance in patients with advanced nonsmall cell lung cancer: A cohort study","volume":"52","author":"Visser","year":"2018","journal-title":"Eur. Respir. J."},{"issue":"2","key":"10.1016\/j.lungcan.2022.10.007_b0040","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.lungcan.2015.05.005","article-title":"Renal insufficiency is the leading cause of double maintenance (bevacizumab and pemetrexed) discontinuation for toxicity to advanced non-small cell lung cancer in real world setting","volume":"89","author":"Sassier","year":"2015","journal-title":"Lung Cancer."},{"issue":"2","key":"10.1016\/j.lungcan.2022.10.007_b0045","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1159\/000455014","article-title":"Adverse renal effects of immune checkpoint inhibitors: A narrative review","volume":"45","author":"Wanchoo","year":"2017","journal-title":"Am. J. Nephrol."},{"issue":"3","key":"10.1016\/j.lungcan.2022.10.007_b0050","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1016\/j.kint.2016.04.008","article-title":"Clinicopathological features of acute kidney injury associated with immune checkpoint inhibitors","volume":"90","author":"Cortazar","year":"2016","journal-title":"Kidney Int."},{"issue":"1","key":"10.1016\/j.lungcan.2022.10.007_b0055","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.kint.2019.07.022","article-title":"Immune checkpoint inhibitor nephrotoxicity: What do we know and what should we do?","volume":"97","author":"Perazella","year":"2020","journal-title":"Kidney Int."},{"key":"10.1016\/j.lungcan.2022.10.007_b0060","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.lungcan.2021.02.021","article-title":"Safety of pemetrexed plus platinum in combination with pembrolizumab for metastatic nonsquamous non-small cell lung cancer: A post hoc analysis of KEYNOTE-189","volume":"155","author":"Garon","year":"2021","journal-title":"Lung Cancer."},{"key":"10.1016\/j.lungcan.2022.10.007_b0065","unstructured":"KDIGO Guidelines. https:\/\/kdigo.org\/guidelines\/Date accessed: April 13, 2022."},{"issue":"1","key":"10.1016\/j.lungcan.2022.10.007_b0070","doi-asserted-by":"crossref","DOI":"10.1186\/s12885-017-3705-7","article-title":"Renal failure during chemotherapy: Renal biopsy for assessing subacute nephrotoxicity of pemetrexed","volume":"17","author":"Assayag","year":"2017","journal-title":"BMC Cancer"},{"issue":"6","key":"10.1016\/j.lungcan.2022.10.007_b0075","doi-asserted-by":"crossref","first-page":"402","DOI":"10.5414\/CN107921","article-title":"Pemetrexed-induced acute kidney injury leading to chronic kidney disease","volume":"82","author":"Chauvet","year":"2014","journal-title":"Clin. Nephrol."},{"issue":"5","key":"10.1016\/j.lungcan.2022.10.007_b0080","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1053\/j.ajkd.2011.04.030","article-title":"Kidney tubular toxicity of maintenance pemetrexed therapy","volume":"58","author":"Glezerman","year":"2011","journal-title":"Am. J. Kidney Dis."},{"key":"10.1016\/j.lungcan.2022.10.007_b0085","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.ejca.2021.01.005","article-title":"Renal adverse effects of immune checkpoints inhibitors in clinical practice: ImmuNoTox study","volume":"147","author":"Espi","year":"2021","journal-title":"Eur. J. Cancer."},{"issue":"1","key":"10.1016\/j.lungcan.2022.10.007_b0090","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1093\/ckj\/sfy100","article-title":"Renal toxicities associated with pembrolizumab","volume":"12","author":"Izzedine","year":"2019","journal-title":"Clin. Kidney J."},{"issue":"1","key":"10.1016\/j.lungcan.2022.10.007_b0095","doi-asserted-by":"crossref","DOI":"10.1186\/s40425-018-0478-8","article-title":"Nephrotoxicity of immune checkpoint inhibitors beyond tubulointerstitial nephritis: Single-center experience","volume":"7","author":"Mamlouk","year":"2019","journal-title":"J. Immunother. Cancer"},{"issue":"1","key":"10.1016\/j.lungcan.2022.10.007_b0100","doi-asserted-by":"crossref","first-page":"e000467","DOI":"10.1136\/jitc-2019-000467","article-title":"Acute kidney injury associated with immune checkpoint inhibitor therapy: Incidence, risk factors and outcomes","volume":"8","author":"Meraz-Mu\u00f1oz","year":"2020","journal-title":"J. Immunother. Cancer."},{"issue":"12","key":"10.1016\/j.lungcan.2022.10.007_b0105","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.2215\/CJN.00990119","article-title":"The incidence, causes, and risk factors of acute kidney injury in patients receiving immune checkpoint inhibitors","volume":"14","author":"Seethapathy","year":"2019","journal-title":"Clin. J. Am. Soc. Nephrol."},{"issue":"1","key":"10.1016\/j.lungcan.2022.10.007_b0110","doi-asserted-by":"crossref","first-page":"16","DOI":"10.34067\/KID.0000152019","article-title":"Acute interstitial nephritis and checkpoint inhibitor therapy: Single center experience of management and drug rechallenge","volume":"1","author":"Manohar","year":"2020","journal-title":"Kidney 360."},{"issue":"22","key":"10.1016\/j.lungcan.2022.10.007_b0115","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1200\/JCO.19.00189","article-title":"Immune checkpoint inhibitor outcomes for patients with non\u2013small-cell lung cancer receiving baseline corticosteroids for palliative versus nonpalliative indications","volume":"37","author":"Ricciuti","year":"2019","journal-title":"JCO"},{"key":"10.1016\/j.lungcan.2022.10.007_b0120","doi-asserted-by":"crossref","unstructured":"De Giglio A, Mezquita L, Auclin E, et al. Impact of Intercurrent Introduction of Steroids on Clinical Outcomes in Advanced Non-Small-Cell Lung Cancer (NSCLC) Patients under Immune-Checkpoint Inhibitors (ICI). Cancers (Basel). 2020;12(10):2827. Published 2020 Sep 30. doi:10.3390\/cancers12102827.","DOI":"10.3390\/cancers12102827"},{"key":"10.1016\/j.lungcan.2022.10.007_b0125","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1002\/path.1711130303","article-title":"Extreme dysplasia in renal epithelium of a young woman dying from hepatocarcinoma","volume":"113","author":"Burry","year":"1974","journal-title":"J. Pathol."},{"issue":"20","key":"10.1016\/j.lungcan.2022.10.007_b0130","doi-asserted-by":"crossref","first-page":"e3349","DOI":"10.1097\/MD.0000000000003349","article-title":"Karyomegalic interstitial nephritis: A case report and review of the literature","volume":"95","author":"Isnard","year":"2016","journal-title":"Medicine (Baltimore)."},{"issue":"4","key":"10.1016\/j.lungcan.2022.10.007_b0135","doi-asserted-by":"crossref","first-page":"294","DOI":"10.4103\/0971-4065.171233","article-title":"Karyomegalic interstitial nephropathy following ifosfamide therapy","volume":"26","author":"Jayasurya","year":"2016","journal-title":"Indian J. Nephrol."},{"issue":"2","key":"10.1016\/j.lungcan.2022.10.007_b0140","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1007\/s13730-014-0124-3","article-title":"Improvement in karyomegalic interstitial nephritis three years after ifosfamide and cisplatin therapy by corticosteroid","volume":"3","author":"Matsuura","year":"2014","journal-title":"CEN Case Rep."},{"issue":"2","key":"10.1016\/j.lungcan.2022.10.007_b0145","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/S1470-2045(20)30641-0","article-title":"First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): An international, randomised, open-label, phase 3 trial","volume":"22","author":"Paz-Ares","year":"2021","journal-title":"Lancet Oncol."},{"issue":"4","key":"10.1016\/j.lungcan.2022.10.007_b0150","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/j.ekir.2017.02.008","article-title":"Anticancer drug-induced acute kidney injury","volume":"2","author":"Izzedine","year":"2017","journal-title":"Kidney Int. Rep."}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500222006675?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500222006675?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T13:02:29Z","timestamp":1759237349000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500222006675"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":30,"alternative-id":["S0169500222006675"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2022.10.007","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2022,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Patterns of renal toxicity from the combination of pemetrexed and pembrolizumab for advanced nonsquamous non-small-cell lung cancer (NSCLC): A single-center experience","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2022.10.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}